Our bold vision is shared by a group of global investors and professionals with years of experience in bringing new medical devices to market.
Funding Snapshot
After initial funding from Sambatech Angel Investors, we raised $24M in Series A funding to advance our robotic platform for open surgery. The syndicate was led by Andera Partners with Panakès Partners, Fountain Healthcare and returning seed investor, Sambatech.
In 2022, we raised approximately $75M in Series B funding to accelerate clinical trials and global commercialization. The round was led by Deerfield Management and RA Capital, with additional funding from existing investors and BioStar Capital. A Series B extension raised an additional $12M led by Wellington Partners and BioStar Capital.
In 2024, we raised $110M in Series C equity financing, representing the largest investment at the time in microsurgery. The round was led by new investor, Fidelity Management & Research Company, with additional funding from existing investors, to support the commercialization of the Symani® Surgical System in large, high-growth markets, as well as continued investment in studies that generate clinical evidence and enable indication expansion.
In 2026, we raised $125M in Series D financing, increasing the total investment to date in MMI to approximately $345M. The round, led by existing investor BioStar Capital, also welcomed several new investors including Angelini Ventures, S3 Ventures and an undisclosed corporate strategic investor. Existing investors participated in the financing as well. Funds will advance the next round of growth for MMI by accelerating commercial expansion in the US and key global markets, broadening patient access to care, and investment in numerous clinical trials, including the REMIND study for Alzheimer’s disease.
